Nymox Pharma (NYMX) Adds to Wednesday's Big Gains

August 25, 2016 8:07 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Nymox Pharma (NASDAQ: NYMX) is up 12% in pre-open trade, adding to yesterday's 83% surge after the company announced successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Momentum Movers, Trader Talk

Related Entities

Pre Market Movers

Add Your Comment